Antimalarials in Lupus Nephritis: How Strong Is the Evidence?
Author Information
Author(s): Fernando Caravaca-Fontán, Federico Yandian, Ladan Zand, Sanjeev Sethi, Fernando C. Fervenza
Hypothesis
What is the strength of the evidence supporting the use of antimalarials in patients with lupus nephritis?
Conclusion
The evidence on antimalarials for disease remission, flare prevention, or kidney failure in patients with lupus nephritis is inadequate.
Supporting Evidence
- Antimalarials are considered a mainstay of therapy for SLE, but evidence for their benefit in lupus nephritis is mainly from observational studies.
- Clinical practice guidelines recommend HCQ for all patients with lupus nephritis, despite limited high-quality evidence.
- Recent studies suggest that the therapeutic benefits of HCQ may be more perception-based than clinically supported.
Takeaway
This study looks at how well antimalarial drugs work for people with kidney problems caused by lupus. It finds that there's not enough good evidence to say they help.
Methodology
The study reviews existing literature on the use of antimalarials in lupus nephritis, assessing the strength of evidence and limitations of previous studies.
Potential Biases
Potential bias due to indication, where patients perceived as lower risk were more likely to receive HCQ.
Limitations
Most studies are observational with small sample sizes and conducted under outdated management practices.
Participant Demographics
Lupus nephritis affects approximately 50% of SLE patients, with higher prevalence in certain populations like African Americans and Asians.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website